Uncover key drivers, emerging technologies, and competitive movements shaping the methylmalonic acidemia (mma) market from 2026–2035 with trusted insights from The Business Research Company
What market expansion outlook does the Methylmalonic Acidemia (MMA) Market show for the 2026–2030 period?
The market for methylmalonic acidemia (mma) has experienced significant expansion in recent years. This market is projected to grow from $9.94 billion in 2025 to $10.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. The historical expansion of the market can be ascribed to several factors, including increased rare disease awareness, the rise of newborn screening programs, the broadening of metabolic disorder research, advancements in diagnostic technologies, and the earlier adoption of genetic testing.
The methylmalonic acidemia (mma) market size is anticipated to undergo significant expansion in the coming years. It is forecast to reach $13.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period is propelled by advancements in precision therapeutics, progress in gene and enzyme replacement therapies, increasing investment in rare disease drug pipelines, the expansion of telehealth-based metabolic monitoring, and a growing focus on personalized nutrition management. Prominent trends expected in this period include the development of precision medicine-based therapies, AI-assisted diagnosis and monitoring, cloud-based integration of rare disease data, automated biomanufacturing for enzyme therapies, and immersive medical training tailored for metabolic disorders.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp
What Drivers Are Shaping The Development Of The Methylmalonic Acidemia (MMA) Market?
The methylmalonic acidemia (MMA) market is projected to grow due to the increasing incidence of metabolic disorders and vitamin deficiencies. Metabolic disorders are health issues where the body struggles to process certain nutrients, create energy, or regulate cellular chemical reactions, while vitamin deficiencies occur when the body lacks sufficient specific vitamins for normal functioning. The rise in these conditions is linked to unhealthy eating habits, inactive lifestyles, and elevated stress levels. Modern diets, frequently high in processed foods, sugars, and unhealthy fats but low in essential nutrients, lead to vitamin and mineral deficiencies. These metabolic disorders and vitamin deficiencies, particularly vitamin B12 deficiency, impair methylmalonyl-CoA metabolism, resulting in the accumulation of methylmalonic acid and aggravating methylmalonic acidemia (MMA). For instance, in November 2024, the National Institutes of Health, a US-based government agency, indicated that the prevalence of vitamin B12 deficiency climbed from 4.6% to 5.2%, signifying an additional 507 cases between the third and fourth quarters of 2023. Therefore, the rising occurrence of metabolic disorders and vitamin deficiencies is a significant factor driving the growth of the methylmalonic acidemia (MMA) market.
Which Segments Are Contributing To The Growth Of The Methylmalonic Acidemia (MMA) Market?
The methylmalonic acidemia (mma) market covered in this report is segmented –
1) By Treatment Type: Dietary Management And Supplementation, Enzyme Replacement Therapy, Gene Therapy, Transplantation
2) By Disorder Type: Isolated Methylmalonic Aciduria, Combined Methylmalonic Aciduria, Homocystinuria
3) By Patient Age Group: Infant, Pediatric, Adult
4) By Route of Administration: Oral, Intravenous
5) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegments:
1) By Dietary Management And Supplementation: Vitamin B12 Supplementation, L-Carnitine Supplementation, Low-Protein Medical Diets
2) By Enzyme Replacement Therapy: Recombinant Enzyme Therapies, Investigational Enzymes
3) By Gene Therapy: AAV-Based Gene Therapy, Other Viral Vector-Based Therapies
4) By Transplantation: Liver Transplantation, Combined Liver–Kidney Transplantation
How Are Emerging Trends Affecting The Progression Of The Methylmalonic Acidemia (MMA) Market?
Leading companies in the methylmalonic acidemia (MMA) market are concentrating on developing innovative solutions, such as mRNA-based therapies. Their goal is to improve treatment outcomes by targeting the underlying genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies utilize messenger RNA to instruct cells to produce specific proteins, which can help prevent or treat diseases like genetic disorders or infections. For instance, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received U.S. Food and Drug Administration (FDA) approval to include mRNA-3705 in the START pilot program. This marks a significant advancement in treatments for rare diseases. mRNA-3705 is an investigational therapy for methylmalonic acidemia (MMA) caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy incorporates Moderna’s proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, thereby facilitating its accelerated development and clinical progress.
Who Are The Prominent Global Companies Shaping The Methylmalonic Acidemia (MMA) Market Landscape?
Major companies operating in the methylmalonic acidemia (mma) market are Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc AskBio, Selecta Biosciences Inc, BridgeBio Pharma Inc., VectivBio Holding AG, Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., LogicBio Therapeutics Inc., Moderna Inc., Wockhardt Limited, Supriya Lifescience Ltd., HemoShear Therapeutics LLC, Deccan Nutraceuticals Pvt Ltd, Genespire, Bluebird Bio Inc, Takeda Pharmaceutical Company Limited, Sanofi, Orphan Technologies Ltd, Ultragenyx Pharmaceutical Inc, HemoShear Therapeutics LLC
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report
How Does The Methylmalonic Acidemia (MMA) Market Perform Across Major Global Regions?
North America was the largest region in the methylmalonic acidemia (MMA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (mma) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Methylmalonic Acidemia (MMA) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp
Browse Through More Reports Similar to the Global Methylmalonic Acidemia (MMA) Market 2026, By The Business Research Company
Hydrochloric Acid Market Report 2026
https://www.thebusinessresearchcompany.com/report/hydrochloric-acid-global-market-report
Alpha Methyldopa Market Report 2026
https://www.thebusinessresearchcompany.com/report/alpha-methyldopa-global-market-report
Glutamic Acid Market Report 2026
https://www.thebusinessresearchcompany.com/report/glutamic-acid-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model